Ignite Creation Date:
2025-12-24 @ 3:20 PM
Ignite Modification Date:
2025-12-25 @ 1:40 PM
Study NCT ID:
NCT03787992
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-04-11
First Post:
2018-12-18
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG）
Sponsor:
Allist Pharmaceuticals, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-05-30
Start Date Type:
ACTUAL
Primary Completion Date:
2021-09-15
Primary Completion Date Type:
ACTUAL
Completion Date:
2026-03
Completion Date Type:
ESTIMATED
First Submit Date:
2018-12-18
First Submit QC Date:
None
Study First Post Date:
2018-12-27
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-04-09
Last Update Post Date:
2025-04-11
Last Update Post Date Type:
ACTUAL